Condition 1: Upper GI bleeding. Condition 2: Upper GI bleeding. Condition 3: Upper GI bleeding. Gastric ulcer Duodenal ulcer Peptic ulcer, site unspecified
Conditions
Interventions
Intervention 1: Intravenous pantoprazole 40 mg with 100 microg subcutaneous octereotide before endoscopy and pantoprazole 40 mg intravenously every 12 hours with Octreotide 100 micrograms subcutaneou
Treatment - Drugs
Placebo
Intravenous pantoprazole 40 mg with 100 microg subcutaneous octereotide before endoscopy and pantoprazole 40 mg intravenously every 12 hours with Octreotide 100 micrograms subcutaneously every 8 hour
Pantoprazole 40 mg intravenously with placebo in the same form and similar and consistent with Octreotide before endoscopy and pantoprazole 40 mg intravenously every 12 hours with subcutaneous placeb
Sponsors
Vice Chancellor of Research, Shiraz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: inclusion criteria: Conscious patients; age between 18 to 80 years; with complaint of melena or hematemesis or tarry stools in rectal examination Exclusion criteria: patients with congestive heart failure class 4; ESRD patients on hemodialysis; pregnant patients; Patients with acute coronary events; nursing patients; cirrhotic Patients with child score B or C; make any complications of treatment with Octreotide at any time during the study; the patient's willingness to withdraw from the study at any time during the study; taking any anticoagulant; patients suffering from coagulation diseases
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Readmission in one month after bleeding. Timepoint: one month. Method of measurement: phone calling.;Mortality in one month after bleeding. Timepoint: one month. Method of measurement: phone calling. | — |
Secondary
| Measure | Time frame |
|---|---|
| Length of hospital admission. Timepoint: daily. Method of measurement: daily visit.;Rate of blood products transfusion. Timepoint: daily. Method of measurement: visit and evaluation amounts of blood products use.;Need for surgery due to bleeding. Timepoint: hospital stay time. Method of measurement: daily visit.;Hospital readmission rate within 30 days after bleeding. Timepoint: weekly for one month. Method of measurement: weekly phone call. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMasoud Abrishami
Shiraz University of Medical Sciences
Outcome results
None listed